Oscar Hernandez Alba

Dr. Oscar Hernandez Alba

Laboratoire de Spectrométrie de Masse BioOrganique (LSMBO), Université de Strasbourg, IPHC, 25 Rue Becquerel, 67087 Strasbourg, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
EDEvolène Deslignière
Evolène Deslignière
AEAnthony Ehkirch
Anthony Ehkirch
BDBastiaan Duivelshof
Bastiaan Duivelshof
HTHanna Toftevall
Hanna Toftevall
JSJonathan Sjögren
Jonathan Sjögren
SSSarah Sanglier-Cianférani
Sarah Sanglier-Cianférani
Antibody-drug conjugates (ADCs) are biotherapeutics consisting of a tumor-targeting monoclonal antibody (mAb) linked covalently to a cytotoxic drug. Early generation ADCs were predominantly obtained through non-selective conjugation methods based on lysine and cysteine residues, resulting in heterogeneous populations with varying drug-to-antibody ratios (DAR). Site-specific conjugation is one of the current challenges in ADC development, allowing for controlled conjugation and production of homogeneous ADCs. We report here the characterization of a site-specific DAR2 ADC generated with the GlyCLICK three-step process, which involves glycan-based enzymatic remodeling and click chemistry, using state-of-the-art native mass spectrometry (nMS) methods. The conjugation process was monitored with size exclusion chromatography coupled to nMS (SEC-nMS), which offered a straightforward identification and quantification of all reaction products, providing a direct snapshot of the ADC homogeneity. Benefits of SEC-nMS were further demonstrated for forced degradation studies, for which fragments generated upon thermal stress were clearly identified, with no deconjugation of the drug linker observed for the T-GlyGLICK-DM1 ADC. Lastly, innovative ion mobility-based collision-induced unfolding (CIU) approaches were used to assess the gas-phase behavior of compounds along the conjugation process, highlighting an increased resistance of the mAb against gas-phase unfolding upon drug conjugation. Altogether, these state-of-the-art nMS methods represent innovative approaches to investigate drug loading and distribution of last generation ADCs, their evolution during the bioconjugation process and their impact on gas-phase stabilities. We envision nMS and CIU methods to improve the conformational characterization of next generation-empowered mAb-derived products such as engineered nanobodies, bispecific ADCs or immunocytokines.

23 May 2022 in Analytical Chemistry
Verified
Journal Article
Open access
EDEvolène Deslignière
Evolène Deslignière
SOSimon Ollivier
Simon Ollivier
AEAnthony Ehkirch
Anthony Ehkirch
AMArmelle Martelet
Armelle Martelet
DRDavid Ropartz
David Ropartz
SSSarah Sanglier-Cianférani
Sarah Sanglier-Cianférani
Multispecific antibodies, which target multiple antigens at once, are emerging as promising therapeutic entities to offer more effective treatment than conventional monoclonal antibodies (mAbs). However, these highly complex mAb formats pose significant analytical challenges. We report here on the characterization of a trispecific antibody (tsAb), which presents two isomeric forms clearly separated and identified with size exclusion chromatography coupled to native mass spectrometry (SEC-nMS). Previous studies showed that these isomers might originate from a proline cis/trans isomerization in one Fab subunit of the tsAb. We combined several innovative ion mobility (IM)-based approaches to confirm the isomeric nature of the two species and to gain new insights into the conformational landscape of both isomers. Preliminary SEC-nIM-MS measurements performed on a low IM resolution instrument provided the first hints of the coexistence of different conformers, while complementary collision-induced unfolding (CIU) experiments evidenced distinct gas-phase unfolding behaviors upon activation for the two isomers. As subtle conformational differences remained poorly resolved on our early generation IM platform, we performed high-resolution cyclic IM (cIM-MS) to unambiguously conclude on the coexistence of two conformers. The cis/trans equilibrium was further tackled by exploiting the IMn slicing capabilities of the cIM-MS instrument. Altogether, our results clearly illustrate the benefits of combining state-of-the-art nMS and IM-MS approaches to address challenging issues encountered in biopharma. As engineered antibody constructs become increasingly sophisticated, CIU and cIM-MS methodologies undoubtedly have the potential to integrate the drug development analytical toolbox to achieve in-depth conformational characterization of these products.

27 November 2023 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
CBCorentin Beaumal
Corentin Beaumal
EDEvolène Deslignière
Evolène Deslignière
HDHélène Diemer
Hélène Diemer
CCChristine Carapito
Christine Carapito
SCSarah Cianférani
Sarah Cianférani
OAOscar Hernandez Alba
Oscar Hernandez Alba

14 November 2023 in Bioconjugate Chemistry
Verified
Journal Article
Open access
ISIrene Shajan
Irene Shajan
LRLéa N. C. Rochet
Léa N. C. Rochet
STShannon R. Tracey
Shannon R. Tracey
BJBianka Jackowska
Bianka Jackowska
RBRania Benazza
Rania Benazza
BABauke Albada
Bauke Albada
Bispecific antibodies as T cell engagers designed to display binding capabilities to both tumor-associated antigens and antigens on T cells are considered promising agents in the fight against cancer. Even though chemical strategies to develop such constructs have emerged, a method that readily converts a therapeutically applied antibody into a bispecific construct by a fully non-genetic process is not yet available. Herein, we report the application of a biogenic, tyrosine-based click reaction utilizing chemoenzymatic modifications of native IgG1 antibodies to generate a synthetic bispecific antibody construct that exhibits tumor-killing capability at picomolar concentrations. Control experiments revealed that a covalent linkage of the different components is required for the observed biological activities. In view of the highly potent nature of the constructs and the modular approach that relies on convenient synthetic methods utilizing therapeutically approved biomolecules, our method expedites the production of potent bispecific antibody constructs with tunable cell killing efficacy with significant impact on therapeutic properties.

10 December 2025 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
ABAlain Beck
Alain Beck
VDValentina D'Atri
Valentina D'Atri
OVOlivier Verhoev
Olivier Verhoev
LALola Alez-Martin
Lola Alez-Martin
LLLéa Letissier
Léa Letissier
OAOscar Hernandez Alba
Oscar Hernandez Alba

16 December 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ABAgathe Boos
Agathe Boos
JMJulien Most
Julien Most
HCHéloïse Cahuzac
Héloïse Cahuzac
LSLouis Moreira da Silva
Louis Moreira da Silva
FDFrançois Daubeuf
François Daubeuf
GCGuilhem Chaubet
Guilhem Chaubet